Zhejiang Shimai Pharmaceutical Refiles for Hong Kong IPO; Core Products DNV3 and SMET12 in Clinical Stage
NewTimeSpace News: Zhejiang Shimai Pharmaceutical Co., Ltd. refiled its main board listing application with the Hong Kong Stock Exchange on May 18, 2026, with Huatai International as the sole sponsor. Founded in 2017, it is a clinical-stage biotech company focused on developing T-cell engager (TCE) therapies, with four clinical-stage pipelines, including two core products DNV3 and SMET12.
NewTimeSpace News: According to Hong Kong Stock Exchange disclosures, Zhejiang Shimai Pharmaceutical Co., Ltd. resubmitted its main board listing application to the Hong Kong Stock Exchange on May 18, 2026, with Huatai International serving as the sole sponsor.
Founded in 2017, Shimai Pharmaceutical is a clinical-stage biotech company specializing in the development of T-cell engager (TCE) therapies. TCEs are bispecific or multispecific antibodies that simultaneously bind to tumor-associated antigens (TAAs) on tumor cells and receptors on T cells, directing T cells to tumor tissue and activating them to induce targeted cytotoxicity. The company has developed masked TCEs that can be selectively activated in tumors for the treatment of solid tumors.
As of the latest practicable date, the company has four independently developed clinical-stage candidate drugs, including two core products:DNV3: A potential best-in-class T-cell modulator (TCM) targeting LAG-3, designed for advanced/metastatic solid tumors and lymphomas. SMET12: A potential first-in-class intravenous EGFR×CD3 TCE for EGFR-positive advanced solid tumors.
Additionally, the company has two preclinical-stage trispecific masked TCE candidates.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- Korean Stocks Open Higher but Close Lower as Semiconductor Heavyweights Slip; Csop Kospi 200 Etf (03121.HK) Falls 1.30%
- AOM INT'L (00381.HK): Launches Twelve Dynasties Wine Project Combining Cultural Export and Digital Assets
- KINETIC DEV (01277.HK): Sierra Leone Rutile Project Commences Production
- CNE TECH CORP (00611.HK): Acquisition Consideration Adjusted Down to RMB71.93m
